Increasing
the odds
Giving everyone diagnosed with cancer, their best chance to become cancer free.
27%
This can lead to inaccurate diagnosis and disease recurrence. Ferronova has developed a surgical oncology tracer system that aims to improve the staging of complex cancers and help increase survival rates.
The gap
More than 40% of people will be diagnosed with cancer during their lifetime. Successful cancer treatment relies on accurate staging of how far, and where cancer has spread from a primary tumour. Current technologies and methods are not able to reliably detect small tumours in lymph nodes
Our solution
Our unique IP technology is a new-generation, polymer-coated magnetic nanoparticle.
This nanoparticle drives a magnetically guided imaging system designed to precisely identify sentinel lymph nodes, to assist surgeons and pathologists to more accurately stage solid tumours and locate and address micro-metastases that may otherwise go undetected
The future of cancer
imaging and surgery
Generate a clear roadmap of the lymphatic system for precise surgical lymph node sampling
Facilitate accurate identification of true sentinel nodes
Enable detection of micro-metastases that would otherwise be missed
Colorectal cancers
The magnetic technology is well suited to complex cancers, where resolution and the ability to locate sentinel lymph nodes close to the injection site are critical.
Our roadmap
May 2016
2020-2022
2023+
Ferronova Incorporated
Feasibility Trials
Pivotal Trials
Our roadmap
May 2016
Ferronova Incorporated
2020-2022
Feasibility Trials
2023+
Pivotal Trials
Clinical trials
Ferronova’s patented polymer-coated iron oxide nanoparticles, made to global standards at a facility in Mawson Lakes, has begun trial at the Royal Adelaide Hospital and Royal Melbourne (Peter MacCallum).
1. Protic M et al. J Am Coll Surg 2015;221(3):643-51.